Direction
Buy
Sell
Types
LMT Order
Price
QTY
Amount
--
ALKS Alkermes
27.100-0.250-0.91%
Close
02/06 16:00 ET
High
27.540
Open
27.330
Turnover
26.54M
Low
26.920
Pre Close
27.350
Volume
978.53K
Intraday
5D
1D
1W
1M
1Q
1Y
Price Forecast
News
Comment
ProShare Advisors LLC Acquires 684 Shares of Alkermes Plc (NASDAQ:ALKS)
ProShare Advisors LLC increased its position in shares of Alkermes plc (NASDAQ:ALKS – Get Rating) by 2.0% in the 3rd quarter, according to the company in its most recent filing with the Securities a
Is There An Opportunity With Alkermes Plc's (NASDAQ:ALKS) 45% Undervaluation?
Victory Capital Management Inc. Trims Position in Alkermes Plc (NASDAQ:ALKS)
Victory Capital Management Inc. lessened its position in shares of Alkermes plc (NASDAQ:ALKS – Get Rating) by 93.9% in the third quarter, according to the company in its most recent Form 13F filing
Alkermes Celebrates Employee Volunteerism Throughout 2022
NORTHAMPTON, MA / ACCESSWIRE / February 2, 2023 / Alkermes is committed to improving the communities where we live and work. Check out this video to see some highlights of our employees' volunteer wor
Alkermes Plc (NASDAQ:ALKS) Shares Purchased by Eagle Asset Management Inc.
Eagle Asset Management Inc. lifted its holdings in shares of Alkermes plc (NASDAQ:ALKS – Get Rating) by 13.6% during the 3rd quarter, Holdings Channel.com reports. The firm owned 855,540 shares of t
Raymond James & Associates Sells 2,220 Shares of Alkermes Plc (NASDAQ:ALKS)
Raymond James & Associates trimmed its stake in Alkermes plc (NASDAQ:ALKS – Get Rating) by 8.2% in the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission (S
How Is the Brain Affected by Alcohol?
NORTHAMPTON, MA / ACCESSWIRE / January 31, 2023 / AlkermesAs Dry January comes to an end, learn more about how alcohol dependence affects the brain in this animation. Also, if you have concerns about
Jefferies Sticks to Their Buy Rating for Alkermes (ALKS)
Alkermes: Nemvaleukin Alfa Granted an Innovation Passport by MHRA
Alkermes Awarded Innovation Passport Designation by the MHRA (UK) for Nemvaleukin Alfa for the Treatment of Mucosal Melanoma
Company Overview
More
Alkermes Plc is a global biopharmaceutical company. It is engaged in the business of developing, manufacturing, and commercializing medicines designed to address unmet medical needs of patients in major therapeutic areas. Its proprietary products include ARISTADA, ARISTADA INITIO, LYBALVI, and VIVITROL. The company was founded in 1987 and is headquartered in Dublin, Ireland.
CEO： Mr. Richard F. Pops
Market： NASDAQ
Listing Date： 09/19/2011
Paper Trade
More
Hot List
TradeSearchNews
SymbolLatest price%Chg
Loading...
Watchlist
No Stock Yet